Login

Access type

Forgot your password? Click here

LOGIN
Annulla
Forgot
DMP_ForgotOK Close

REGISTER

If you are a doctor or a journalist not yet registered at the Dompé reserved areas, click here to fill in the form.

REGISTER
Follow LinkedIn YouTube

News

 
On its 73rd anniversary, Dompé announces D-Day, its new social responsibility programme, in which the company’s employees will be the protagonists of a day dedicated to sharing and solidarity.

1940-2013: sensitise by innovating.
On its 73rd anniversary, Dompé announces D-Day, its new social responsibility programme, in which the company’s employees will be the protagonists of a day dedicated to sharing and solidarity

  • Dompé’s new social responsibility project gets under way with the company’s employees acting as “exceptional volunteers” for a day dedicated to informing, understanding and sensitising.
  • Dompé Day has been organised in collaboration with the no-profit organisations, the Foundation for Cystic Fibrosis Research (FFC) and the Italian Union of the Blind and Partially Sighted.
  • Milan and L’Aquila united under the banner of responsibility: in Milan, five piazzas and hundreds of lighted balloons for fund raising; in L’Aquila, “mini-Olympics” to overcome prejudices and understand the reality surrounding us from a new point of view.

Milan, 12 November 2013 - Five piazzas in Milan to sensitise the Milanese to cystic fibrosis and the therapeutic needs of the people affected by it. The L’Aquila site transformed into an arena designed to illustrate the everyday challenges face by the blind and people with visual impairments. The involvement of the employees of Dompé, one of the leading biopharmaceutical companies in Italy, will unite the two cities under the banner of social solidarity.
The occasion is the “birthday” of the Group, which was founded in Milan on 14 November 1940. And it is next 14 November that the company’s employees will – for the first time – become testimonials of a large-scale project of corporate social responsibility aimed at highlighting the role that each can play in raising awareness of the hot areas of healthcare and the impact that certain diseases and conditions has on the life of the people affected by them.
The company’s partners in the project are two no-profit organisations: the Foundation for Cystic Fibrosis Research and the Italian Union of the Blind and Partially Sighted. These are therapeutic areas to which Dompé has long dedicated itself: it has a historical commitment to improving the quality of life of patients with respiratory diseases such cystic fibrosis and, starting from the work of the Nobel prize winner Rita Levi Montalcini, Dompé’s researchers have developed recombinant human nerve growth factor (rhNGF), which is currently in an advanced stage of clinical testing for the treatment of neurotrophic keratitis and has recently been recognised as an orphan drug for the treatment of retinitis pigmentosa, two serious eye diseases that have so far been without any effective treatment.

“Dompé Day is our day for others. A day that will our employees in the front line as testimonials of solidarity and promoters of two important events,” explained Nathalie Dompé, the Dompé Group Corporate Social Responsibility Manager. “Looking after our employees, the real resource behind the development of the Group, and being dedicated to what are often still unmet healthcare needs, lie at the heart of Dompé’s everyday activities. And we are proud of collaborating with two such important no-profit organisations as the Foundation for Cystic Fibrosis Research and the Italian Union of the Blind and Partially Sighted on this special day in the history of the Group”.

In Milan, D-Day will see Dompé employees manning information stands that will bring colour to five of the city’s piazzas: Piazza Cairoli, Piazza Argentina, Piazza Leonardo Da Vinci, Largo La Foppa, and Piazza Oberdan. At the end of the day, 73 lighted balloons will be released into the sky to celebrate the anniversary and symbolically counterpoint the lightness of air against the harshness of the disease.

“We are particularly pleased to collaborate with Dompé for this special day” said Matteo Marzotto, entrepreneur and co-founder of the Foundation for Cystic Fibrosis Research. “Cystic fibrosis is the most common serious genetic disease: it affects 7,000 people in Italy alone, with 200 new cases every year, and there is still no definitive therapy for it. The role of information is fundamental in helping us to maintain the public’s awareness of this severe disease, and D-Day is a perfect way of doing this with commitment and enthusiasm and by making an active contribution to our mission of solidarity”.

At the site in L’Aquila, Dompé’s employees will be involved in a series of activities aimed at giving them an insight into the world of everyday challenges faced by the blind and visually impaired. This “how” mirrors the innovative approach underlying D-Day: ten teams will participate in the dark in a sort of mini-Olympic games that will test their sense of touch, smell, hearing and taste. The event will finish with an archery competition between sighted and visually impaired archers in order to “target” prejudices.
“The Italian Union of the Blind and Partially Sighted enthusiastically welcomed the challenge of Dompé,” said Americo Montanaro, President of the organisation’s L’Aquila Provincial Council. “The greatest obstacle for blind and visually impaired people is prejudice. For this reason, we are keen to participate in this initiative aimed at sensitising people by having them enjoy themselves by being together and putting themselves to the test. These are the principles underlying the Union, which every day fights to break down the real and metaphorical barriers of the surrounding world”.
D-Day is a further step in the development of Dompé’s corporate social responsibility policy after project “GENIale: designing the future with biotechnology”, which involved more than 600 children attending L’Aquila’s middle schools by means of an art competition and offered important lessons for the development of a scientific understanding of the biotechnologies.